# Antonio Oliver

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 322 papers | 21,252 citations | 9786 — 73 h-index | 14208 — 128 g-index |
| 351 all docs | 351 docs citations | 351 times ranked | 19882 citing authors |

| # | ARTICLE | IF | CITATIONS |
|---|---|---|---|
| 1 | Comparative analysis of <i>in vitro</i> dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in <i>Pseudomonas aeruginosa</i> XDR high-risk clones. Journal of Antimicrobial Chemotherapy, 2022, 77, 957-968. | 3.0 | 14 |
| 2 | Boosting the sensitivity of paper-based biosensors with polymeric water-soluble reservoirs. Sensors and Actuators B: Chemical, 2022, 354, 131214. | 7.8 | 4 |
| 3 | Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable Pseudomonas aeruginosa via a Dynamic Biofilm Model and Mechanism-Based Modeling. Antimicrobial Agents and Chemotherapy, 2022, 66, aac0220321. | 3.2 | 4 |
| 4 | Mammals' humoral immune proteins and peptides targeting the bacterial envelope: from natural protection to therapeutic applications against multidrugâ€resistant <scp>Gram</scp>â€negatives. Biological Reviews, 2022, 97, 1005-1037. | 10.4 | 5 |
| 5 | Selection of AmpC Î²-Lactamase Variants and Metallo-Î²-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0206721. | 3.2 | 28 |
| 6 | Impact of Peptidoglycan Recycling Blockade and Expression of Horizontally Acquired Î²-Lactamases on Pseudomonas aeruginosa Virulence. Microbiology Spectrum, 2022, 10, e0201921. | 3.0 | 8 |
| 7 | Susceptibility profiles and resistance genomics of <i>Pseudomonas aeruginosa</i> isolates from European ICUs participating in the ASPIRE-ICU trial. Journal of Antimicrobial Chemotherapy, 2022, 77, 1862-1872. | 3.0 | 23 |
| 8 | Rapid Identification and Classification of Pathogens That Produce Carbapenemases and Cephalosporinases with a Colorimetric Paper-Based Multisensor. Analytical Chemistry, 2022, 94, 9442-9449. | 6.5 | 8 |
| 9 | Recommendations of the Spanish Antibiogram Committee (COESANT) for in vitro susceptibility testing of antimicrobial agents by disk diffusion. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2022, , . | 0.5 | 0 |
| 10 | <i>In vivo</i> translational assessment of the GES genotype on the killing profile of ceftazidime, ceftazidime/avibactam and meropenem against <i>Pseudomonas aeruginosa</i>. Journal of Antimicrobial Chemotherapy, 2022, 77, 2803-2808. | 3.0 | 7 |
| 11 | Molecular mechanisms driving the<i>in vivo</i>development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR<i>Pseudomonas aeruginosa</i>infections. Journal of Antimicrobial Chemotherapy, 2021, 76, 91-100. | 3.0 | 38 |
| 12 | Bedside Detection of Carbapenemase-Producing Pathogens with Plasmonic Nanosensors. Sensors and Actuators B: Chemical, 2021, 329, 129059. | 7.8 | 10 |
| 13 | Distinct epidemiology and resistance mechanisms affecting ceftolozane/tazobactam in<i>Pseudomonas aeruginosa</i>isolates recovered from ICU patients in Spain and Portugal depicted by WGS. Journal of Antimicrobial Chemotherapy, 2021, 76, 370-379. | 3.0 | 14 |
| 14 | Optimized detection of lung IL-6 <i>via</i> enzymatic liquefaction of low respiratory tract samples: application for managing ventilated patients. Analyst, The, 2021, 146, 6537-6546. | 3.5 | 2 |
| 15 | Panbioâ„¢ rapid antigen test for SARS-CoV-2 has acceptable accuracy in symptomatic patients in primary health care. Journal of Infection, 2021, 82, 391-398. | 3.3 | 53 |
| 16 | Molecular Basis of AmpC Î²-Lactamase Induction by Avibactam in Pseudomonas aeruginosa: PBP Occupancy, Live Cell Binding Dynamics and Impact on Resistant Clinical Isolates Harboring PDC-X Variants. International Journal of Molecular Sciences, 2021, 22, 3051. | 4.1 | 7 |
| 17 | Immunodetection of Lung IgG and IgM Antibodies against SARS-CoV-2 via Enzymatic Liquefaction of Respiratory Samples from COVID-19 Patients. Analytical Chemistry, 2021, 93, 5259-5266. | 6.5 | 8 |
| 18 | 6-Halopyridylmethylidene Penicillin-Based Sulfones Efficiently Inactivate the Natural Resistance of <i>Pseudomonas aeruginosa</i> to Î²-Lactam Antibiotics. Journal of Medicinal Chemistry, 2021, 64, 6310-6328. | 6.4 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Rapid evolution and host immunity drive the rise and fall of carbapenem resistance during an acute Pseudomonas aeruginosa infection. Nature Communications, 2021, 12, 2460. | 12.8 | 47 |
| 20 | <i>Pseudomonas aeruginosa</i>: a clinical and genomics update. FEMS Microbiology Reviews, 2021, 45, . | 8.6 | 26 |
| 21 | Use of Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry Analysis of Serum Peptidome to Classify and Predict Coronavirus Disease 2019 Severity. Open Forum Infectious Diseases, 2021, 8, ofab222. | 0.9 | 3 |
| 22 | Combination versus monotherapy as definitive treatment for <i>Pseudomonas aeruginosa</i> bacteraemia: a multicentre retrospective observational cohort study. Journal of Antimicrobial Chemotherapy, 2021, 76, 2172-2181. | 3.0 | 19 |
| 23 | Metagenomics Analysis Reveals an Extraordinary Inner Bacterial Diversity in Anisakids (Nematoda:) Tj ETQq1 1 0.784314 rgBT /Overlo | 3.6 | 4 |
| 24 | Predicting Pseudomonas aeruginosa susceptibility phenotypes from whole genome sequence resistome analysis. Clinical Microbiology and Infection, 2021, 27, 1631-1637. | 6.0 | 36 |
| 25 | Validation of MALDI-TOF for the early detection of the ST175 high-risk clone of Pseudomonas aeruginosa in clinical isolates belonging to a Spanish nationwide multicenter study. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2021, 39, 279-282. | 0.5 | 4 |
| 26 | Spread of a SARS-CoV-2 variant through Europe in the summer of 2020. Nature, 2021, 595, 707-712. | 27.8 | 363 |
| 27 | Validation of MALDI-TOF for the early detection of the ST175 high-risk clone of Pseudomonas aeruginosa in clinical isolates belonging to a Spanish nationwide multicenter study. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed ), 2021, 39, 279-282. | 0.3 | 2 |
| 28 | <i>In vitro</i>evolution of cefepime/zidebactam (WCK 5222) resistance in<i>Pseudomonas aeruginosa</i>: dynamics, mechanisms, fitness trade-off and impact on<i>in vivo</i>efficacy. Journal of Antimicrobial Chemotherapy, 2021, 76, 2546-2557. | 3.0 | 11 |
| 29 | Emergence of Resistance to Novel Cephalosporinâ€"Î²-Lactamase Inhibitor Combinations through the Modification of the Pseudomonas aeruginosa MexCD-OprJ Efflux Pump. Antimicrobial Agents and Chemotherapy, 2021, 65, e0008921. | 3.2 | 29 |
| 30 | Predictive Immunological, Virological, and Routine Laboratory Markers for Critical COVID-19 on Admission. Canadian Journal of Infectious Diseases and Medical Microbiology, 2021, 2021, 1-8. | 1.9 | 7 |
| 31 | <i>In Vivo</i> Evolution of GES Î²-Lactamases Driven by Ceftazidime/Avibactam Treatment of Pseudomonas aeruginosa Infections. Antimicrobial Agents and Chemotherapy, 2021, 65, e0098621. | 3.2 | 14 |
| 32 | Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates. Microbiology Spectrum, 2021, 9, e0058521. | 3.0 | 18 |
| 33 | The first wave of the COVID-19 epidemic in Spain was associated with early introductions and fast spread of a dominating genetic variant. Nature Genetics, 2021, 53, 1405-1414. | 21.4 | 35 |
| 34 | Pharmacodynamics of ceftazidime plus tobramycin combination dosage regimens against hypermutable Pseudomonas aeruginosa isolates at simulated epithelial lining fluid concentrations in a dynamic in vitro infection model. Journal of Global Antimicrobial Resistance, 2021, 26, 55-63. | 2.2 | 7 |
| 35 | Recommendations for antibiotic selection for severe nosocomial infections. Revista Espanola De Quimioterapia, 2021, 34, 511-524. | 1.3 | 8 |
| 36 | A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?. Infectious Diseases and Therapy, 2021, 10, 2677-2699. | 4.0 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Whole-genome sequence-guided PCR for the rapid identification of the<i>Pseudomonas aeruginosa</i>ST175 high-risk clone directly from clinical samples. Journal of Antimicrobial Chemotherapy, 2021, 76, 945-949. | 3.0 | 2 |
| 38 | Pseudomonas aeruginosa Susceptibility in Spain: Antimicrobial Activity and Resistance Suppression Evaluation by PK/PD Analysis. Pharmaceutics, 2021, 13, 1899. | 4.5 | 5 |
| 39 | Inhaled corticosteroid use and its association with Pseudomonas aeruginosa infection in COPD. , 2021, , . | | 0 |
| 40 | Impact of ceftolozane/tazobactam concentrations in continuous infusion against extensively drug-resistant Pseudomonas aeruginosa isolates in a hollow-fiber infection model. Scientific Reports, 2021, 11, 22178. | 3.3 | 6 |
| 41 | A Genomic Snapshot of the SARS-CoV-2 Pandemic in the Balearic Islands. Frontiers in Microbiology, 2021, 12, 803827. | 3.5 | 3 |
| 42 | Multicenter Performance Evaluation of MALDI-TOF MS for Rapid Detection of Carbapenemase Activity in Enterobacterales: The Future of Networking Data Analysis With Online Software. Frontiers in Microbiology, 2021, 12, 789731. | 3.5 | 4 |
| 43 | Molecular Analysis of the Contribution of Alkaline Protease A and Elastase B to the Virulence of Pseudomonas aeruginosa Bloodstream Infections. Frontiers in Cellular and Infection Microbiology, 2021, 11, 816356. | 3.9 | 7 |
| 44 | Del CLSI al EUCAST, una transiciÃ³n necesaria en los laboratorios espaÃ±oles. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2020, 38, 79-83. | 0.5 | 11 |
| 45 | Long-term Persistence of an Extensively Drug-Resistant Subclade of Globally Distributed Pseudomonas aeruginosa Clonal Complex 446 in an Academic Medical Center. Clinical Infectious Diseases, 2020, 71, 1524-1531. | 5.8 | 20 |
| 46 | Weighting the impact of virulence on the outcome of Pseudomonas aeruginosa bloodstream infections. Clinical Microbiology and Infection, 2020, 26, 351-357. | 6.0 | 11 |
| 47 | Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for Pseudomonas aeruginosa Bloodstream Infection: A Multisite Retrospective Study. Clinical Infectious Diseases, 2020, 70, 2270-2280. | 5.8 | 24 |
| 48 | A Standard Numbering Scheme for Class C Î$^2$-Lactamases. Antimicrobial Agents and Chemotherapy, 2020, 64, . | 3.2 | 50 |
| 49 | From CLSI to EUCAST, a necessary step in Spanish laboratories. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed ), 2020, 38, 79-83. | 0.3 | 2 |
| 50 | Minimum information guideline for spectrophotometric and fluorometric methods to assess biofilm formation in microplates. Biofilm, 2020, 2, 100010. | 3.8 | 50 |
| 51 | Pathogenic characteristics of Pseudomonas aeruginosa bacteraemia isolates in a high-endemicity setting for ST175 and ST235 high-risk clones. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 671-678. | 2.9 | 15 |
| 52 | Emergence of high-level and stable metronidazole resistance in Clostridioides difficile. International Journal of Antimicrobial Agents, 2020, 55, 105830. | 2.5 | 4 |
| 53 | Risk factors for mortality among patients with Pseudomonas aeruginosa bacteraemia: a retrospective multicentre study. International Journal of Antimicrobial Agents, 2020, 55, 105847. | 2.5 | 33 |
| 54 | Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired Î$^2$-lactamases: 2020 update. International Journal of Antimicrobial Agents, 2020, 56, 106196. | 2.5 | 147 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Mobile origami immunosensors for the rapid detection of urinary tract infections. Analyst, The, 2020, 145, 7916-7921. | 3.5 | 11 |
| 56 | Adding Insult to Injury: Mechanistic Basis for How AmpC Mutations Allow Pseudomonas aeruginosa To Accelerate Cephalosporin Hydrolysis and Evade Avibactam. Antimicrobial Agents and Chemotherapy, 2020, 64, . | 3.2 | 27 |
| 57 | Recommendations of the Spanish Antibiogram Committee (COESANT) for selecting antimicrobial agents and concentrations for in vitro susceptibility studies using automated systems. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed ), 2020, 38, 182-187. | 0.3 | 0 |
| 58 | Rapid Detection of <i>Pseudomonas aeruginosa</i> Biofilms via Enzymatic Liquefaction of Respiratory Samples. ACS Sensors, 2020, 5, 3956-3963. | 7.8 | 17 |
| 59 | Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR Pseudomonas aeruginosa infection. Journal of Antimicrobial Chemotherapy, 2020, 75, 3209-3217. | 3.0 | 26 |
| 60 | WGS characterization of MDR Enterobacterales with different ceftolozane/tazobactam susceptibility profiles during the SUPERIOR surveillance study in Spain. JAC-Antimicrobial Resistance, 2020, 2, dlaa084. | 2.1 | 7 |
| 61 | Temperate Bacteriophages (Prophages) in Pseudomonas aeruginosa Isolates Belonging to the International Cystic Fibrosis Clone (CC274). Frontiers in Microbiology, 2020, 11, 556706. | 3.5 | 18 |
| 62 | A Genome-Based Model to Predict the Virulence of Pseudomonas aeruginosa Isolates. MBio, 2020, 11, . | 4.1 | 12 |
| 63 | Clinically Relevant Epithelial Lining Fluid Concentrations of Meropenem with Ciprofloxacin Provide Synergistic Killing and Resistance Suppression of Hypermutable Pseudomonas aeruginosa in a Dynamic Biofilm Model. Antimicrobial Agents and Chemotherapy, 2020, 64, . | 3.2 | 7 |
| 64 | Efficacy of Ceftolozane-Tazobactam in Combination with Colistin against Extensively Drug-Resistant Pseudomonas aeruginosa, Including High-Risk Clones, in an <i>In Vitro</i> Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2020, 64, . | 3.2 | 8 |
| 65 | Nosocomial outbreak linked to a flexible gastrointestinal endoscope contaminated with an amikacin-resistant ST17 clone of Pseudomonas aeruginosa. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 1837-1844. | 2.9 | 11 |
| 66 | Carbapenemase-producing Pseudomonas aeruginosa in Spain: interregional dissemination of the high-risk clones ST175 and ST244 carrying blaVIM-2, blaVIM-1, blaIMP-8, blaVIM-20 and blaKPC-2. International Journal of Antimicrobial Agents, 2020, 56, 106026. | 2.5 | 27 |
| 67 | In vitro dynamics and mechanisms of resistance development to imipenem and imipenem/relebactam in Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2020, 75, 2508-2515. | 3.0 | 24 |
| 68 | Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet, The, 2020, 396, 535-544. | 13.7 | 1,465 |
| 69 | Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic Î²-Lactam-Resistant Mutants. Antimicrobial Agents and Chemotherapy, 2020, 64, . | 3.2 | 54 |
| 70 | Effective inhibition of PBPs by cefepime and zidebactam in the presence of VIM-1 drives potent bactericidal activity against MBL-expressing Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2020, 75, 1474-1478. | 3.0 | 26 |
| 71 | In vitro and in vivo efficacy of combinations of colistin and different endolysins against clinical strains of multi-drug resistant pathogens. Scientific Reports, 2020, 10, 7163. | 3.3 | 54 |
| 72 | Characterization of AmpC Î²-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2020, 38, 474-478. | 0.5 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Predicting antimicrobial resistance in <i>Pseudomonas aeruginosa</i> with machine learningâ€enabled molecular diagnostics. EMBO Molecular Medicine, 2020, 12, e10264. | 6.9 | 111 |
| 74 | Recommendations of the Spanish Antibiogram Committee (COESANT) for selecting antimicrobial agents and concentrations for in vitro susceptibility studies using automated systems. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2020, 38, 182-187. | 0.5 | 6 |
| 75 | Characterization of AmpC Î²-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed ), 2020, 38, 474-478. | 0.3 | 1 |
| 76 | Activity of mammalian peptidoglycan-targeting immunity against Pseudomonas aeruginosa. Journal of Medical Microbiology, 2020, 69, 492-504. | 1.8 | 5 |
| 77 | Role of inhaled corticosteroids on recurrent bronchial infection by potentially pathogenic bacteria in patients with COPD. , 2020, , . | | 0 |
| 78 | Four Decades of Î²-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis. Clinical Pharmacokinetics, 2019, 58, 143-156. | 3.5 | 15 |
| 79 | Association between Pseudomonas aeruginosa O-antigen serotypes, resistance profiles and high-risk clones: results from a Spanish nationwide survey. Journal of Antimicrobial Chemotherapy, 2019, 74, 3217-3220. | 3.0 | 18 |
| 80 | Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable Pseudomonas aeruginosa at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model. Antimicrobial Agents and Chemotherapy, 2019, 63, . | 3.2 | 11 |
| 81 | Challenging Antimicrobial Susceptibility and Evolution of Resistance (OXA-681) during Treatment of a Long-Term Nosocomial Infection Caused by a Pseudomonas aeruginosa ST175 Clone. Antimicrobial Agents and Chemotherapy, 2019, 63, . | 3.2 | 22 |
| 82 | Therapeutic Efficacy of LN-1-255 in Combination with Imipenem in Severe Infection Caused by Carbapenem-Resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 2019, 63, . | 3.2 | 9 |
| 83 | In Vivo Validation of Peptidoglycan Recycling as a Target to Disable AmpC-Mediated Resistance and Reduce Virulence Enhancing the Cell-Wallâ€“Targeting Immunity. Journal of Infectious Diseases, 2019, 220, 1729-1737. | 4.0 | 18 |
| 84 | Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections. Clinical Microbiology Reviews, 2019, 32, . | 13.6 | 489 |
| 85 | Comparative Analysis of Peptidoglycans From Pseudomonas aeruginosa Isolates Recovered From Chronic and Acute Infections. Frontiers in Microbiology, 2019, 10, 1868. | 3.5 | 12 |
| 86 | Evaluation of Tobramycin and Ciprofloxacin as a Synergistic Combination Against Hypermutable Pseudomonas Aeruginosa Strains via Mechanism-Based Modelling. Pharmaceutics, 2019, 11, 470. | 4.5 | 4 |
| 87 | Higher MICs (>2 mg/L) Predict 30-Day Mortality in Patients With Lower Respiratory Tract Infections Caused by Multidrug- and Extensively Drug-Resistant Pseudomonas aeruginosa Treated With Ceftolozane/Tazobactam. Open Forum Infectious Diseases, 2019, 6, ofz416. | 0.9 | 22 |
| 88 | O-antigen serotyping and MALDI-TOF, potentially useful tools for optimizing semi-empiric antipseudomonal treatments through the early detection of high-risk clones. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 541-544. | 2.9 | 17 |
| 89 | Colistin plus meropenem combination is synergistic in vitro against extensively drug-resistant Pseudomonas aeruginosa, including high-risk clones. Journal of Global Antimicrobial Resistance, 2019, 18, 37-44. | 2.2 | 16 |
| 90 | Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology. Journal of Antimicrobial Chemotherapy, 2019, 74, 1825-1835. | 3.0 | 92 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Profiling the susceptibility of Pseudomonas aeruginosa strains from acute and chronic infections to cell-wall-targeting immune proteins. Scientific Reports, 2019, 9, 3575. | 3.3 | 10 |
| 92 | Social Behavior of Antibiotic Resistant Mutants Within Pseudomonas aeruginosa Biofilm Communities. Frontiers in Microbiology, 2019, 10, 570. | 3.5 | 21 |
| 93 | <i>In Vitro</i> and <i>In Vivo</i> Activities of Î²-Lactams in Combination with the Novel Î²-Lactam Enhancers Zidebactam and WCK 5153 against Multidrug-Resistant Metallo-Î²-Lactamase-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2019, 63, . | 3.2 | 35 |
| 94 | Characterization of Hypermutator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia. Antimicrobial Agents and Chemotherapy, 2019, 63, . | 3.2 | 30 |
| 95 | Regulation of AmpC-Driven Î²-Lactam Resistance in Pseudomonas aeruginosa: Different Pathways, Different Signaling. MSystems, 2019, 4, . | 3.8 | 53 |
| 96 | Emergence of Resistance to Novel Î²-Lactamâ€“Î²-Lactamase Inhibitor Combinations Due to Horizontally Acquired AmpC (FOX-4) in <i>Pseudomonas aeruginosa</i> Sequence Type 308. Antimicrobial Agents and Chemotherapy, 2019, 64, . | 3.2 | 10 |
| 97 | Identifying and exploiting genes that potentiate the evolution of antibiotic resistance. Nature Ecology and Evolution, 2018, 2, 1033-1039. | 7.8 | 41 |
| 98 | Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing <i>Escherichia coli</i> and ESBL-Producing <i>Klebsiella pneumoniae</i>. Infection Control and Hospital Epidemiology, 2018, 39, 660-667. | 1.8 | 49 |
| 99 | Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2018, 62, . | 3.2 | 31 |
| 100 | Phenylboronic Acid Derivatives as Validated Leads Active in Clinical Strains Overexpressing KPCâ€2: A Step against Bacterial Resistance. ChemMedChem, 2018, 13, 713-724. | 3.2 | 24 |
| 101 | Evolution of the Pseudomonas aeruginosa Aminoglycoside Mutational Resistome In Vitro and in the Cystic Fibrosis Setting. Antimicrobial Agents and Chemotherapy, 2018, 62, . | 3.2 | 44 |
| 102 | Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2018, 73, 658-663. | 3.0 | 157 |
| 103 | Evaluation of Ceftolozane-Tazobactam in Combination with Meropenem against Pseudomonas aeruginosa Sequence Type 175 in a Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2018, 62, . | 3.2 | 21 |
| 104 | Increased Antimicrobial Resistance in a Novel CMY-54 AmpC-Type Enzyme with a GluLeu<sup>217â€“218</sup> Insertion in the Î©-Loop. Microbial Drug Resistance, 2018, 24, 527-533. | 2.0 | 4 |
| 105 | Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms. Antimicrobial Agents and Chemotherapy, 2018, 62, . | 3.2 | 21 |
| 106 | Antimicrobial stewardship in Spain: Programs for Optimizing the use of Antibiotics (PROA) in Spanish hospitals. Germs, 2018, 8, 109-112. | 1.3 | 7 |
| 107 | Deciphering Î²-lactamase-independent Î²-lactam resistance evolution trajectories in Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2018, 73, 3322-3331. | 3.0 | 27 |
| 108 | Interplay between Peptidoglycan Biology and Virulence in Gram-Negative Pathogens. Microbiology and Molecular Biology Reviews, 2018, 82, . | 6.6 | 36 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum Î²-lactamase-producing Enterobacteriaceae. International Journal of Antimicrobial Agents, 2018, 52, 577-585. | 2.5 | 36 |
| 110 | Susceptibility to R-pyocins of Pseudomonas aeruginosa clinical isolates from cystic fibrosis patients. Journal of Antimicrobial Chemotherapy, 2018, 73, 2770-2776. | 3.0 | 19 |
| 111 | The Versatile Mutational Resistome of Pseudomonas aeruginosa. Frontiers in Microbiology, 2018, 9, 685. | 3.5 | 181 |
| 112 | Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 2191-2200. | 2.9 | 53 |
| 113 | Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients. Antimicrobial Agents and Chemotherapy, 2018, 62, . | 3.2 | 26 |
| 114 | MÃ©todos microbiolÃ³gicos para la vigilancia del estado de portador de bacterias multirresistentes. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2017, 35, 667-675. | 0.5 | 24 |
| 115 | Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-<b>Î²</b>-lactamase-producing Enterobacteriaceae. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw513. | 3.0 | 46 |
| 116 | Activity of ceftazidimeâ€“avibactam against multidrug-resistance Enterobacteriaceae expressing combined mechanisms of resistance. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2017, 35, 499-504. | 0.5 | 13 |
| 117 | EpidemiologÃa y mecanismos de resistencia a carbapenemas en Pseudomonas aeruginosa : papel de los clones de alto riesgo en la multirresistencia. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2017, 35, 137-138. | 0.5 | 8 |
| 118 | Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infectious Diseases, The, 2017, 17, 726-734. | 9.1 | 367 |
| 119 | Antibiotic treatment of biofilm infections. Apmis, 2017, 125, 304-319. | 2.0 | 299 |
| 120 | Understanding the acute inflammatory response to Pseudomonas aeruginosa infection: differences between susceptible and multidrug-resistant strains in a mouse peritonitis model. International Journal of Antimicrobial Agents, 2017, 49, 198-203. | 2.5 | 12 |
| 121 | Epidemiology and carbapenem resistance mechanisms in Pseudomonas aeruginosa : Role of high-risk clones in multidrug resistance. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed ), 2017, 35, 137-138. | 0.3 | 5 |
| 122 | Host and Pathogen Biomarkers for Severe Pseudomonas aeruginosa Infections. Journal of Infectious Diseases, 2017, 215, S44-S51. | 4.0 | 116 |
| 123 | Determining Î²-lactam exposure threshold to suppress resistance development in Gram-negative bacteria. Journal of Antimicrobial Chemotherapy, 2017, 72, 1421-1428. | 3.0 | 72 |
| 124 | WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent â€œÎ²-Lactam Enhancerâ€• Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-Î²-Lactamase-Producing High-Risk Clones. Antimicrobial Agents and Chemotherapy, 2017, 61, . | 3.2 | 92 |
| 125 | Synergistic activity of fosfomycin, Î²-lactams and peptidoglycan recycling inhibition against<i>Pseudomonas aeruginosa</i>. Journal of Antimicrobial Chemotherapy, 2017, 72, 448-454. | 3.0 | 25 |
| 126 | Insights into the evolution of the mutational resistome of <i>Pseudomonas aeruginosa</i> in cystic fibrosis. Future Microbiology, 2017, 12, 1445-1448. | 2.0 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Activity of ceftazidimeâ€¢avibactam against multidrug-resistance Enterobacteriaceae expressing combined mechanisms of resistance. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed ), 2017, 35, 497-502. | 0.3 | 0 |
| 128 | Diversity and regulation of intrinsic Î²-lactamases from non-fermenting and other Gram-negative opportunistic pathogens. FEMS Microbiology Reviews, 2017, 41, 781-815. | 8.6 | 83 |
| 129 | Potent Î²-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2017, 61, . | 3.2 | 57 |
| 130 | Prevalence of quinolone resistance mechanisms in Enterobacteriaceae producing acquired AmpC Î²-lactamases and/or carbapenemases in Spain. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed ), 2017, 35, 485-490. | 0.3 | 4 |
| 131 | Draft Genome Sequences of Four Pseudomonas aeruginosa Isolates Obtained from Patients with Chronic Obstructive Pulmonary Disease. Genome Announcements, 2017, 5, . | 0.8 | 1 |
| 132 | Interplay among Resistance Profiles, High-Risk Clones, and Virulence in the Caenorhabditis elegansPseudomonas aeruginosa Infection Model. Antimicrobial Agents and Chemotherapy, 2017, 61, . | 3.2 | 39 |
| 133 | Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain. Antimicrobial Agents and Chemotherapy, 2017, 61, . | 3.2 | 108 |
| 134 | Antibiotic resistance and population structure of cystic fibrosis Pseudomonas aeruginosa isolates from a Spanish multi-centre study. International Journal of Antimicrobial Agents, 2017, 50, 334-341. | 2.5 | 20 |
| 135 | Evolution of the Pseudomonas aeruginosa mutational resistome in an international Cystic Fibrosis clone. Scientific Reports, 2017, 7, 5555. | 3.3 | 117 |
| 136 | Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. International Journal of Antimicrobial Agents, 2017, 50, 664-672. | 2.5 | 8 |
| 137 | Microbiological methods for surveillance of carrier status of multiresistant bacteria. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed ), 2017, 35, 667-675. | 0.3 | 8 |
| 138 | <i>In Vivo</i> Emergence of Resistance to Novel Cephalosporinâ€"Î²-Lactamase Inhibitor Combinations through the Duplication of Amino Acid D149 from OXA-2 Î²-Lactamase (OXA-539) in Sequence Type 235 Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2017, 61, . | 3.2 | 61 |
| 139 | Prevalencia en EspaÃ±a de mecanismos de resistencia a quinolonas en enterobacterias productoras de betalactamasas de clase C adquiridas y/o carbapenemasas. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2017, 35, 487-492. | 0.5 | 8 |
| 140 | Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum Î²-Lactamaseâ€"Producing Enterobacteriaceae: Results From the INCREMENT Cohort. Clinical Infectious Diseases, 2017, 65, 1615-1623. | 5.8 | 43 |
| 141 | Targeting the permeability barrier and peptidoglycan recycling pathways to disarm Pseudomonas aeruginosa against the innate immune system. PLoS ONE, 2017, 12, e0181932. | 2.5 | 32 |
| 142 | Impact of multidrug resistance on the pathogenicity of Pseudomonas aeruginosa: in vitro and in vivo studies. International Journal of Antimicrobial Agents, 2016, 47, 368-374. | 2.5 | 30 |
| 143 | Sequential Treatment of Biofilms with Aztreonam and Tobramycin Is a Novel Strategy for Combating Pseudomonas aeruginosa Chronic Respiratory Infections. Antimicrobial Agents and Chemotherapy, 2016, 60, 2912-2922. | 3.2 | 25 |
| 144 | A Multinational, Preregistered Cohort Study of Î²-Lactam/Î²-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-Î²-Lactamase-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2016, 60, 4159-4169. | 3.2 | 137 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable<i>Pseudomonas aeruginosa</i>. Journal of Antimicrobial Chemotherapy, 2016, 71, 3157-3167. | 3.0 | 26 |
| 146 | Surfactant Protein A Recognizes Outer Membrane Protein OprH on<i>Pseudomonas aeruginosa</i>Isolates From Individuals With Chronic Infection. Journal of Infectious Diseases, 2016, 214, 1449-1455. | 4.0 | 17 |
| 147 | A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae. Mayo Clinic Proceedings, 2016, 91, 1362-1371. | 3.0 | 89 |
| 148 | Deciphering the Resistome of the Widespread Pseudomonas aeruginosa Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing. Antimicrobial Agents and Chemotherapy, 2016, 60, 7415-7423. | 3.2 | 99 |
| 149 | Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant Î²-Lactam Resistance Mechanisms. Antimicrobial Agents and Chemotherapy, 2016, 60, 6407-6410. | 3.2 | 47 |
| 150 | Impact of AmpC Derepression on Fitness and Virulence: the Mechanism or the Pathway?. MBio, 2016, 7, . | 4.1 | 62 |
| 151 | Nosocomial dissemination of VIM-2-producing ST235 Pseudomonas aeruginosa in Lithuania. European Journal of Clinical Microbiology and Infectious Diseases, 2016, 35, 195-200. | 2.9 | 21 |
| 152 | VIM-47, a New Variant of the Autochthonous Metallo-Î²-Lactamase VIM-13 from the Balearic Islands in Spain. Antimicrobial Agents and Chemotherapy, 2016, 60, 3251-3252. | 3.2 | 3 |
| 153 | Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. Journal of Antimicrobial Chemotherapy, 2016, 71, 1672-1680. | 3.0 | 41 |
| 154 | Evolution of Pseudomonas aeruginosa Antimicrobial Resistance and Fitness under Low and High Mutation Rates. Antimicrobial Agents and Chemotherapy, 2016, 60, 1767-1778. | 3.2 | 170 |
| 155 | Comprehensive clinical and epidemiological assessment of colonisation and infection due to carbapenemase-producing Enterobacteriaceae in Spain. Journal of Infection, 2016, 72, 152-160. | 3.3 | 73 |
| 156 | Bronchopulmonary infectionâ€"colonization patterns in Spanish cystic fibrosis patients: Results from a national multicenter study. Journal of Cystic Fibrosis, 2016, 15, 357-365. | 0.7 | 16 |
| 157 | Genotypic and phenotypic analyses of a Pseudomonas aeruginosa chronic bronchiectasis isolate reveal differences from cystic fibrosis and laboratory strains. BMC Genomics, 2015, 16, 883. | 2.8 | 30 |
| 158 | Using the Electronic Nose to Identify Airway Infection during COPD Exacerbations. PLoS ONE, 2015, 10, e0135199. | 2.5 | 62 |
| 159 | Molecular identification of aminoglycoside-modifying enzymes in clinical isolates of Escherichia coli resistant to amoxicillin/clavulanic acid isolated in Spain. International Journal of Antimicrobial Agents, 2015, 46, 157-163. | 2.5 | 36 |
| 160 | Consenso espaÃ±ol para la prevenciÃ³n y el tratamiento de la infecciÃ³n bronquial por Pseudomonas aeruginosa en el paciente con fibrosis quÃstica. Archivos De Bronconeumologia, 2015, 51, 140-150. | 0.8 | 35 |
| 161 | The problems of antibiotic resistance in cystic fibrosis and solutions. Expert Review of Respiratory Medicine, 2015, 9, 73-88. | 2.5 | 49 |
| 162 | Spanish Consensus on the Prevention and Treatment of Pseudomonas aeruginosa Bronchial Infections in Cystic Fibrosis Patients. Archivos De Bronconeumologia, 2015, 51, 140-150. | 0.8 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Clinical relevance of Pseudomonas aeruginosa hypermutation in cystic fibrosis chronic respiratory infection. Journal of Cystic Fibrosis, 2015, 14, e1-e2. | 0.7 | 4 |
| 164 | Mobile Genetic Elements Related to the Diffusion of Plasmid-Mediated AmpC Î²-Lactamases or Carbapenemases from Enterobacteriaceae: Findings from a Multicenter Study in Spain. Antimicrobial Agents and Chemotherapy, 2015, 59, 5260-5266. | 3.2 | 19 |
| 165 | Rates of faecal colonization by carbapenemase-producing Enterobacteriaceae among patients admitted to ICUs in Spain: Table 1.. Journal of Antimicrobial Chemotherapy, 2015, 70, 2916-2918. | 3.0 | 11 |
| 166 | Role of Pseudomonas aeruginosa Low-Molecular-Mass Penicillin-Binding Proteins in AmpC Expression, Î²-Lactam Resistance, and Peptidoglycan Structure. Antimicrobial Agents and Chemotherapy, 2015, 59, 3925-3934. | 3.2 | 75 |
| 167 | <i>N</i>-Acetylcysteine Selectively Antagonizes the Activity of Imipenem in Pseudomonas aeruginosa by an OprD-Mediated Mechanism. Antimicrobial Agents and Chemotherapy, 2015, 59, 3246-3251. | 3.2 | 16 |
| 168 | Prospective Multicenter Study of Carbapenemase-Producing Enterobacteriaceae from 83 Hospitals in Spain Reveals High <i>In Vitro</i> Susceptibility to Colistin and Meropenem. Antimicrobial Agents and Chemotherapy, 2015, 59, 3406-3412. | 3.2 | 130 |
| 169 | Two Mechanisms of Killing of Pseudomonas aeruginosa by Tobramycin Assessed at Multiple Inocula via Mechanism-Based Modeling. Antimicrobial Agents and Chemotherapy, 2015, 59, 2315-2327. | 3.2 | 76 |
| 170 | <i>In vivo</i>evolution of resistance of<i>Pseudomonas aeruginosa</i>strains isolated from patients admitted to an intensive care unit: mechanisms of resistance and antimicrobial exposure. Journal of Antimicrobial Chemotherapy, 2015, 70, 3004-3013. | 3.0 | 39 |
| 171 | The increasing threat of Pseudomonas aeruginosa high-risk clones. Drug Resistance Updates, 2015, 21-22, 41-59. | 14.4 | 475 |
| 172 | Draft Genome Sequence of the Quorum-Sensing and Biofilm-Producing Pseudomonas aeruginosa Strain Pae221, Belonging to the Epidemic High-Risk Clone Sequence Type 274. Genome Announcements, 2015, 3, . | 0.8 | 5 |
| 173 | Influence of Virulence Genotype and Resistance Profile in the Mortality of Pseudomonas aeruginosa Bloodstream Infections. Clinical Infectious Diseases, 2015, 60, 539-548. | 5.8 | 153 |
| 174 | Platelet-Rich Plasma in a Patient with Cerebral Palsy. American Journal of Case Reports, 2015, 16, 469-472. | 0.8 | 14 |
| 175 | Comparison of Local Features from Two Spanish Hospitals Reveals Common and Specific Traits at Multiple Levels of the Molecular Epidemiology of Metallo-Î²-Lactamase-Producing Pseudomonas spp. Antimicrobial Agents and Chemotherapy, 2014, 58, 4992-4992. | 3.2 | 1 |
| 176 | Microbiological diagnostic procedures for respiratory cystic fibrosis samples in Spain: towards standard of care practices. BMC Microbiology, 2014, 14, 335. | 3.3 | 8 |
| 177 | Breakpoints for carbapenemase-producing Enterobacteriaceae: Is the problem solved?. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2014, 32, 33-40. | 0.5 | 14 |
| 178 | Pseudomonas aeruginosa Ceftolozane-Tazobactam Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural Modification of AmpC. Antimicrobial Agents and Chemotherapy, 2014, 58, 3091-3099. | 3.2 | 197 |
| 179 | Inhibitor-Resistant TEM- and OXA-1-Producing Escherichia coli Isolates Resistant to Amoxicillin-Clavulanate Are More Clonal and Possess Lower Virulence Gene Content than Susceptible Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2014, 58, 3874-3881. | 3.2 | 23 |
| 180 | Comparison of Local Features from Two Spanish Hospitals Reveals Common and Specific Traits at Multiple Levels of the Molecular Epidemiology of Metallo-Î²-Lactamase-Producing Pseudomonas spp. Antimicrobial Agents and Chemotherapy, 2014, 58, 2454-2458. | 3.2 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Genetic and Kinetic Characterization of the Novel AmpC Î²-Lactamases DHA-6 and DHA-7. Antimicrobial Agents and Chemotherapy, 2014, 58, 6544-6549. | 3.2 | 7 |
| 182 | Overexpression of MexCD-OprJ Reduces Pseudomonas aeruginosa Virulence by Increasing Its Susceptibility to Complement-Mediated Killing. Antimicrobial Agents and Chemotherapy, 2014, 58, 2426-2429. | 3.2 | 23 |
| 183 | A randomized trial of intravenous glutamine supplementation in trauma ICU patients. Intensive Care Medicine, 2014, 40, 539-547. | 8.2 | 33 |
| 184 | Antimicrobial susceptibility testing in biofilm-growing bacteria. Clinical Microbiology and Infection, 2014, 20, 981-990. | 6.0 | 391 |
| 185 | Characterization of a novel Zn2+-dependent intrinsic imipenemase from Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2014, 69, 2972-2978. | 3.0 | 26 |
| 186 | Hypermutation in Burkholderia cepacia complex is mediated by DNA mismatch repair inactivation and is highly prevalent in cystic fibrosis chronic respiratory infection. International Journal of Medical Microbiology, 2014, 304, 1182-1191. | 3.6 | 30 |
| 187 | Minimum information about a biofilm experiment (MIABiE): standards for reporting experiments and data on sessile microbial communities living at interfaces. Pathogens and Disease, 2014, 70, 250-256. | 2.0 | 43 |
| 188 | The Pseudomonas aeruginosa CreBC Two-Component System Plays a Major Role in the Response to Î²-Lactams, Fitness, Biofilm Growth, and Global Regulation. Antimicrobial Agents and Chemotherapy, 2014, 58, 5084-5095. | 3.2 | 56 |
| 189 | Draft Genome Sequence of Colistin-Only-Susceptible Pseudomonas aeruginosa Strain ST235, a Hypervirulent High-Risk Clone in Spain. Genome Announcements, 2014, 2, . | 0.8 | 4 |
| 190 | Structure and interaction with phospholipids of a prokaryotic lipoxygenase from <i>Pseudomonas aeruginosa</i>. FASEB Journal, 2013, 27, 4811-4821. | 0.5 | 78 |
| 191 | Molecular Epidemiology and Multidrug Resistance Mechanisms of <i>Pseudomonas aeruginosa</i> Isolates from Bulgarian Hospitals. Microbial Drug Resistance, 2013, 19, 355-361. | 2.0 | 45 |
| 192 | Effect of Adequate Single-Drug vs Combination Antimicrobial Therapy on Mortality in Pseudomonas aeruginosa Bloodstream Infections: A Post Hoc Analysis of a Prospective Cohort. Clinical Infectious Diseases, 2013, 57, 208-216. | 5.8 | 135 |
| 193 | Selective trihydroxyazepane NagZ inhibitors increase sensitivity of Pseudomonas aeruginosa to Î²-lactams. Chemical Communications, 2013, 49, 10983. | 4.1 | 36 |
| 194 | Prevalence and molecular epidemiology of acquired AmpC Î²-lactamases and carbapenemases in Enterobacteriaceae isolates from 35 hospitals in Spain. European Journal of Clinical Microbiology and Infectious Diseases, 2013, 32, 253-259. | 2.9 | 91 |
| 195 | Antimicrobial stewardship programs: A public health priority in Spain. The SEIMC-REIPI initiative. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2013, 31, 1-2. | 0.5 | 5 |
| 196 | Molecular epidemiology and resistance profiles of Clostridium difficile in a tertiary care hospital in Spain. International Journal of Medical Microbiology, 2013, 303, 128-133. | 3.6 | 25 |
| 197 | Inappropriate use of antibiotics in hospitals: The complex relationship between antibiotic use and antimicrobial resistance. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2013, 31, 3-11. | 0.5 | 68 |
| 198 | First detection in Europe of the metallo-Î²-lactamase IMP-15 in clinical strains of Pseudomonas putida and Pseudomonas aeruginosa. Clinical Microbiology and Infection, 2013, 19, E424-E427. | 6.0 | 27 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Draft Genome Sequence of VIM-2-Producing Multidrug-Resistant Pseudomonas aeruginosa ST175, an Epidemic High-Risk Clone. Genome Announcements, 2013, 1, e0011213. | 0.8 | 9 |
| 200 | Challenges for accurate susceptibility testing, detection and interpretation of Â-lactam resistance phenotypes in Pseudomonas aeruginosa: results from a Spanish multicentre study. Journal of Antimicrobial Chemotherapy, 2013, 68, 619-630. | 3.0 | 20 |
| 201 | Characterization of the New AmpC Î²-Lactamase FOX-8 Reveals a Single Mutation, Phe313Leu, Located in the R2 Loop That Affects Ceftazidime Hydrolysis. Antimicrobial Agents and Chemotherapy, 2013, 57, 5158-5161. | 3.2 | 8 |
| 202 | First Report of an OXA-23 Carbapenemase-Producing Acinetobacter baumannii Clinical Isolate Related to Tn2006in Spain. Antimicrobial Agents and Chemotherapy, 2013, 57, 589-591. | 3.2 | 23 |
| 203 | Biological Markers of Pseudomonas aeruginosa Epidemic High-Risk Clones. Antimicrobial Agents and Chemotherapy, 2013, 57, 5527-5535. | 3.2 | 104 |
| 204 | Epidemiological and Clinical Complexity of Amoxicillin-Clavulanate-Resistant Escherichia coli. Journal of Clinical Microbiology, 2013, 51, 2414-2417. | 3.9 | 13 |
| 205 | High Î²-Lactamase Levels Change the Pharmacodynamics of Î²-Lactam Antibiotics in Pseudomonas aeruginosa Biofilms. Antimicrobial Agents and Chemotherapy, 2013, 57, 196-204. | 3.2 | 69 |
| 206 | A trade-off between oxidative stress resistance and DNA repair plays a role in the evolution of elevated mutation rates in bacteria. Proceedings of the Royal Society B: Biological Sciences, 2013, 280, 20130007. | 2.6 | 40 |
| 207 | Clonal Dissemination, Emergence of Mutator Lineages and Antibiotic Resistance Evolution in Pseudomonas aeruginosa Cystic Fibrosis Chronic Lung Infection. PLoS ONE, 2013, 8, e71001. | 2.5 | 69 |
| 208 | Prospective Multicenter Study of the Impact of Carbapenem Resistance on Mortality in Pseudomonas aeruginosa Bloodstream Infections. Antimicrobial Agents and Chemotherapy, 2012, 56, 1265-1272. | 3.2 | 123 |
| 209 | Intrinsic and Environmental Mutagenesis Drive Diversification and Persistence of Pseudomonas aeruginosa in Chronic Lung Infections. Journal of Infectious Diseases, 2012, 205, 121-127. | 4.0 | 61 |
| 210 | Spanish Multicenter Study of the Epidemiology and Mechanisms of Amoxicillin-Clavulanate Resistance in Escherichia coli. Antimicrobial Agents and Chemotherapy, 2012, 56, 3576-3581. | 3.2 | 49 |
| 211 | Alterations of OprD in Carbapenem-Intermediate and -Susceptible Strains of Pseudomonas aeruginosa Isolated from Patients with Bacteremia in a Spanish Multicenter Study. Antimicrobial Agents and Chemotherapy, 2012, 56, 1703-1713. | 3.2 | 111 |
| 212 | Genetic Markers of Widespread Extensively Drug-Resistant Pseudomonas aeruginosa High-Risk Clones. Antimicrobial Agents and Chemotherapy, 2012, 56, 6349-6357. | 3.2 | 189 |
| 213 | Transferable Multidrug Resistance Plasmid Carrying <i>cfr</i> Associated with <i>tet</i> (L), <i>ant(4</i> â€² <i>)-Ia</i> , and <i>dfrK</i> Genes from a Clinical Methicillin-Resistant Staphylococcus aureus ST125 Strain. Antimicrobial Agents and Chemotherapy, 2012, 56, 2139-2142. | 3.2 | 47 |
| 214 | Characterization of a Novel IMP-28 Metallo-Î²-Lactamase from a Spanish Klebsiella oxytoca Clinical Isolate. Antimicrobial Agents and Chemotherapy, 2012, 56, 4540-4543. | 3.2 | 12 |
| 215 | <i>In Vivo</i> Selection of Moxifloxacin-Resistant Clostridium difficile. Antimicrobial Agents and Chemotherapy, 2012, 56, 2788-2789. | 3.2 | 4 |
| 216 | Antibiotic pressure compensates the biological cost associated with Pseudomonas aeruginosa hypermutable phenotypes in vitro and in a murine model of chronic airways infection. Journal of Antimicrobial Chemotherapy, 2012, 67, 962-969. | 3.0 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | Pan-Î²-Lactam Resistance Development in Pseudomonas aeruginosa Clinical Strains: Molecular Mechanisms, Penicillin-Binding Protein Profiles, and Binding Affinities. Antimicrobial Agents and Chemotherapy, 2012, 56, 4771-4778. | 3.2 | 138 |
| 218 | Unusual Diversity of Acquired Î²-lactamases in Multidrug-ResistantPseudomonas aeruginosaIsolates in a Mexican Hospital. Microbial Drug Resistance, 2012, 18, 471-478. | 2.0 | 15 |
| 219 | VIM-2â€“producing Multidrug-Resistant<i>Pseudomonas aeruginosa</i>ST175 Clone, Spain. Emerging Infectious Diseases, 2012, 18, 1235-41. | 4.3 | 59 |
| 220 | Colonisation and infection due to Enterobacteriaceae producing plasmid-mediated AmpC Î²-lactamases. Journal of Infection, 2012, 64, 176-183. | 3.3 | 45 |
| 221 | Providing Î²-lactams a helping hand: targeting the AmpC Î²-lactamase induction pathway. Future Microbiology, 2011, 6, 1415-1427. | 2.0 | 61 |
| 222 | Nontypable Haemophilus influenzae Displays a Prevalent Surface Structure Molecular Pattern in Clinical Isolates. PLoS ONE, 2011, 6, e21133. | 2.5 | 22 |
| 223 | Evolution and Adaptation in Pseudomonas aeruginosa Biofilms Driven by Mismatch Repair System-Deficient Mutators. PLoS ONE, 2011, 6, e27842. | 2.5 | 53 |
| 224 | Development of antibiotic resistance and up-regulation of the antimutator gene pfpI in mutator Pseudomonas aeruginosa due to inactivation of two DNA oxidative repair genes (mutY, mutM). FEMS Microbiology Letters, 2011, 324, 28-37. | 1.8 | 18 |
| 225 | A large sustained endemic outbreak of multiresistant Pseudomonas aeruginosa: a new epidemiological scenario for nosocomial acquisition. BMC Infectious Diseases, 2011, 11, 272. | 2.9 | 54 |
| 226 | Wide Dispersion of ST175 Clone despite High Genetic Diversity of Carbapenem-Nonsusceptible Pseudomonas aeruginosa Clinical Strains in 16 Spanish Hospitals. Journal of Clinical Microbiology, 2011, 49, 2905-2910. | 3.9 | 76 |
| 227 | Meropenem Penetration into Epithelial Lining Fluid in Mice and Humans and Delineation of Exposure Targets. Antimicrobial Agents and Chemotherapy, 2011, 55, 3406-3412. | 3.2 | 40 |
| 228 | Antagonistic Interactions of Pseudomonas aeruginosa Antibiotic Resistance Mechanisms in Planktonic but Not Biofilm Growth. Antimicrobial Agents and Chemotherapy, 2011, 55, 4560-4568. | 3.2 | 58 |
| 229 | Overexpression of AmpC and Efflux Pumps in Pseudomonas aeruginosa Isolates from Bloodstream Infections: Prevalence and Impact on Resistance in a Spanish Multicenter Study. Antimicrobial Agents and Chemotherapy, 2011, 55, 1906-1911. | 3.2 | 168 |
| 230 | Environmental Microbiota Represents a Natural Reservoir for Dissemination of Clinically Relevant Metallo-Î²-Lactamases. Antimicrobial Agents and Chemotherapy, 2011, 55, 5376-5379. | 3.2 | 55 |
| 231 | Dynamics of Mutator and Antibiotic-Resistant Populations in a Pharmacokinetic/Pharmacodynamic Model of Pseudomonas aeruginosa Biofilm Treatment. Antimicrobial Agents and Chemotherapy, 2011, 55, 5230-5237. | 3.2 | 60 |
| 232 | Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem. Journal of Antimicrobial Chemotherapy, 2011, 66, 2022-2027. | 3.0 | 132 |
| 233 | AmpG Inactivation Restores Susceptibility of Pan-Î²-Lactam-Resistant Pseudomonas aeruginosa Clinical Strains. Antimicrobial Agents and Chemotherapy, 2011, 55, 1990-1996. | 3.2 | 47 |
| 234 | Expression of Toll-Like Receptors 2 and 4 is Upregulated During Hospital Admission in Traumatic Patients. Annals of Surgery, 2010, 251, 521-527. | 4.2 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | Carrier detection and prenatal diagnosis of congenital adrenal hyperplasia must identify â€˜apparently mildâ€™ CYP21A2 alleles which associate neonatal saltâ€wasting disease. Prenatal Diagnosis, 2010, 30, 758-763. | 2.3 | 11 |
| 236 | Bacterial hypermutation in cystic fibrosis, not only for antibiotic resistance. Clinical Microbiology and Infection, 2010, 16, 798-808. | 6.0 | 162 |
| 237 | THE EFFECT OF ELEVATED MUTATION RATES ON THE EVOLUTION OF COOPERATION AND VIRULENCE OF<i>PSEUDOMONAS AERUGINOSA</i>. Evolution; International Journal of Organic Evolution, 2010, 64, 515-521. | 2.3 | 32 |
| 238 | Assessing the Emergence of Resistance: The Absence of Biological Cost In Vivo May Compromise Fosfomycin Treatments for P. aeruginosa Infections. PLoS ONE, 2010, 5, e10193. | 2.5 | 37 |
| 239 | NagZ Inactivation Prevents and Reverts Î²-Lactam Resistance, Driven by AmpD and PBP 4 Mutations, in <i>Pseudomonas aeruginosa</i>. Antimicrobial Agents and Chemotherapy, 2010, 54, 3557-3563. | 3.2 | 61 |
| 240 | Risk Factors and Prognosis of Nosocomial Bloodstream Infections Caused by Extended-Spectrum-Î²-Lactamase-Producing <i>Escherichia coli</i>. Journal of Clinical Microbiology, 2010, 48, 1726-1731. | 3.9 | 144 |
| 241 | Differential Â-lactam resistance response driven by ampD or dacB (PBP4) inactivation in genetically diverse Pseudomonas aeruginosa strains. Journal of Antimicrobial Chemotherapy, 2010, 65, 1540-1542. | 3.0 | 42 |
| 242 | Role of changes in the L3 loop of the active site in the evolution of enzymatic activity of VIM-type metallo-Â-lactamases. Journal of Antimicrobial Chemotherapy, 2010, 65, 1950-1954. | 3.0 | 29 |
| 243 | <i>ampG</i> Gene of <i>Pseudomonas aeruginosa</i> and Its Role in Î²-Lactamase Expression. Antimicrobial Agents and Chemotherapy, 2010, 54, 4772-4779. | 3.2 | 48 |
| 244 | Affinity of the New Cephalosporin CXA-101 to Penicillin-Binding Proteins of <i>Pseudomonas aeruginosa</i>. Antimicrobial Agents and Chemotherapy, 2010, 54, 3933-3937. | 3.2 | 88 |
| 245 | Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1. Journal of Antimicrobial Chemotherapy, 2010, 65, 1399-1404. | 3.0 | 37 |
| 246 | Activity of a New Antipseudomonal Cephalosporin, CXA-101 (FR264205), against Carbapenem-Resistant and Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Clinical Strains. Antimicrobial Agents and Chemotherapy, 2010, 54, 846-851. | 3.2 | 85 |
| 247 | Communityâ€Onset Bacteremia Due to Extendedâ€Spectrum Î²â€Lactamaseâ€“Producing<i>Escherichia coli:</i>Risk Factors and Prognosis. Clinical Infectious Diseases, 2010, 50, 40-48. | 5.8 | 294 |
| 248 | Activity of a New Cephalosporin, CXA-101 (FR264205), against Î²-Lactam-Resistant <i>Pseudomonas aeruginosa</i> Mutants Selected <i>In Vitro</i> and after Antipseudomonal Treatment of Intensive Care Unit Patients. Antimicrobial Agents and Chemotherapy, 2010, 54, 1213-1217. | 3.2 | 96 |
| 249 | Metallo-Â-lactamase-producing Pseudomonas putida as a reservoir of multidrug resistance elements that can be transferred to successful Pseudomonas aeruginosa clones. Journal of Antimicrobial Chemotherapy, 2010, 65, 474-478. | 3.0 | 105 |
| 250 | Mutators in cystic fibrosis chronic lung infection: Prevalence, mechanisms, and consequences for antimicrobial therapy. International Journal of Medical Microbiology, 2010, 300, 563-572. | 3.6 | 79 |
| 251 | Chronic colonization by Pseudomonas aeruginosa of patients with obstructive lung diseases: cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. Diagnostic Microbiology and Infectious Disease, 2010, 68, 20-27. | 1.8 | 72 |
| 252 | Nosocomial Outbreak of a Non-Cefepime-Susceptible Ceftazidime-Susceptible Pseudomonas aeruginosa Strain Overexpressing MexXY-OprM and Producing an Integron-Borne PSE-1 ÃŸ-Lactamase. Journal of Clinical Microbiology, 2009, 47, 2381-2387. | 3.9 | 35 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | Î²-Lactam Resistance Response Triggered by Inactivation of a Nonessential Penicillin-Binding Protein. PLoS Pathogens, 2009, 5, e1000353. | 4.7 | 258 |
| 254 | Optical Music Recognition for Scores Written in White Mensural Notation. Eurasip Journal on Image and Video Processing, 2009, 2009, 1-23. | 2.6 | 28 |
| 255 | Escherichia coli producing SHV-type extended-spectrum Â-lactamase is a significant cause of community-acquired infection. Journal of Antimicrobial Chemotherapy, 2009, 63, 781-784. | 3.0 | 24 |
| 256 | Inactivation of the hmgA gene of Pseudomonas aeruginosa leads to pyomelanin hyperproduction, stress resistance and increased persistence in chronic lung infection. Microbiology (United Kingdom), 2009, 155, 1050-1057. | 1.8 | 124 |
| 257 | Azithromycin in <i>Pseudomonas aeruginosa</i> Biofilms: Bactericidal Activity and Selection of <i>nfxB</i> Mutants. Antimicrobial Agents and Chemotherapy, 2009, 53, 1552-1560. | 3.2 | 73 |
| 258 | Detection of the Novel Extended-Spectrum Î²-Lactamase OXA-161 from a Plasmid-Located Integron in<i>Pseudomonas aeruginosa</i>Clinical Isolates from Spain. Antimicrobial Agents and Chemotherapy, 2009, 53, 5288-5290. | 3.2 | 25 |
| 259 | Inactivation of the Glycoside Hydrolase NagZ Attenuates Antipseudomonal Î²-Lactam Resistance in <i>Pseudomonas aeruginosa</i>. Antimicrobial Agents and Chemotherapy, 2009, 53, 2274-2282. | 3.2 | 65 |
| 260 | Extended-spectrum Î²-lactamase-producing Escherichia coli in Spain belong to a large variety of multilocus sequence typing types, including ST10 complex/A, ST23 complex/A and ST131/B2. International Journal of Antimicrobial Agents, 2009, 34, 173-176. | 2.5 | 164 |
| 261 | Nosocomial Spread of Colistin-Only-Sensitive Sequence Type 235 <i>Pseudomonas aeruginosa</i> Isolates Producing the Extended-Spectrum Î²-Lactamases GES-1 and GES-5 in Spain. Antimicrobial Agents and Chemotherapy, 2009, 53, 4930-4933. | 3.2 | 91 |
| 262 | Chronic<i>Pseudomonas aeruginosa</i>Infection in Chronic Obstructive Pulmonary Disease. Clinical Infectious Diseases, 2008, 47, 1526-1533. | 5.8 | 235 |
| 263 | Benefit of Having Multiple<i>ampD</i>Genes for Acquiring Î²-Lactam Resistance without Losing Fitness and Virulence in<i>Pseudomonas aeruginosa</i>. Antimicrobial Agents and Chemotherapy, 2008, 52, 3694-3700. | 3.2 | 91 |
| 264 | Genetic Adaptation of <i>Pseudomonas aeruginosa</i> to the Airways of Cystic Fibrosis Patients Is Catalyzed by Hypermutation. Journal of Bacteriology, 2008, 190, 7910-7917. | 2.2 | 219 |
| 265 | <i>Pseudomonas aeruginosa</i> RsmA Plays an Important Role during Murine Infection by Influencing Colonization, Virulence, Persistence, and Pulmonary Inflammation. Infection and Immunity, 2008, 76, 632-638. | 2.2 | 92 |
| 266 | Characterization of plasmids encoding blaESBL and surrounding genes in Spanish clinical isolates of Escherichia coli and Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy, 2008, 63, 60-66. | 3.0 | 66 |
| 267 | Community Infections Caused by Extended-Spectrum Î²-Lactamaseâ€“Producing Escherichia coli. Archives of Internal Medicine, 2008, 168, 1897. | 3.8 | 333 |
| 268 | Chronic Respiratory Infections by Mucoid Carbapenemase-Producing <i>Pseudomonas aeruginosa</i> Strains, a New Potential Public Health Problem. Antimicrobial Agents and Chemotherapy, 2008, 52, 2285-2286. | 3.2 | 12 |
| 269 | Characterization of the New Metallo-Î²-Lactamase VIM-13 and Its Integron-Borne Gene from a <i>Pseudomonas aeruginosa</i> Clinical Isolate in Spain. Antimicrobial Agents and Chemotherapy, 2008, 52, 3589-3596. | 3.2 | 71 |
| 270 | Novel Phosphorylcholineâ€Containing Protein of<i>Pseudomonas aeruginosa</i>Chronic Infection Isolates Interacts with Airway Epithelial Cells. Journal of Infectious Diseases, 2008, 197, 465-473. | 4.0 | 52 |

| # | Article | IF | Citations |
|---|---|---|---|
| 271 | Inactivation of the Mismatch Repair System in Pseudomonas aeruginosa Attenuates Virulence but Favors Persistence of Oropharyngeal Colonization in Cystic Fibrosis Mice. Journal of Bacteriology, 2007, 189, 3665-3668. | 2.2 | 48 |
| 272 | Improvement in Growth after Two Years of Growth Hormone Therapy in Very Young Children Born Small for Gestational Age and without Spontaneous Catch-Up Growth: Results of a Multicenter, Controlled, Randomized, Open Clinical Trial. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3095-3101. | 3.6 | 44 |
| 273 | Influence of High Mutation Rates on the Mechanisms and Dynamics of In Vitro and In Vivo Resistance Development to Single or Combined Antipseudomonal Agents. Antimicrobial Agents and Chemotherapy, 2007, 51, 2574-2581. | 3.2 | 34 |
| 274 | Biological cost of hypermutation in Pseudomonas aeruginosa strains from patients with cystic fibrosis. Microbiology (United Kingdom), 2007, 153, 1445-1454. | 1.8 | 85 |
| 275 | Increased Susceptibility to Colistin in Hypermutable <i>Pseudomonas aeruginosa</i> Strains from Chronic Respiratory Infections. Antimicrobial Agents and Chemotherapy, 2007, 51, 4531-4532. | 3.2 | 8 |
| 276 | Molecular Epidemiology and Mechanisms of Carbapenem Resistance in <i>Pseudomonas aeruginosa</i> Isolates from Spanish Hospitals. Antimicrobial Agents and Chemotherapy, 2007, 51, 4329-4335. | 3.2 | 161 |
| 277 | P880 Single-step selection of double mutations leading to high antibiotic-resistance in hyper-mutable Pseudomonas aeruginosa. International Journal of Antimicrobial Agents, 2007, 29, S227-S228. | 2.5 | 0 |
| 278 | Coevolution with viruses drives the evolution of bacterial mutation rates. Nature, 2007, 450, 1079-1081. | 27.8 | 263 |
| 279 | Molecular epidemiology of methicillin-resistant Staphylococcus aureus in Majorcan hospitals: high prevalence of the epidemic clone EMRSA-15. Clinical Microbiology and Infection, 2007, 13, 599-605. | 6.0 | 22 |
| 280 | Nosocomial spread of Pseudomonas aeruginosa producing the metallo-Î²-lactamase VIM-2 in a Spanish hospital: clinical and epidemiological implications. Clinical Microbiology and Infection, 2007, 13, 1026-1029. | 6.0 | 35 |
| 281 | PBP3 inhibition elicits adaptive responses in Pseudomonas aeruginosa. Molecular Microbiology, 2006, 62, 84-99. | 2.5 | 97 |
| 282 | Efficacy and Potential for Resistance Selection of Antipseudomonal Treatments in a Mouse Model of Lung Infection by Hypermutable Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2006, 50, 975-983. | 3.2 | 77 |
| 283 | Characterization of a Large Outbreak by CTX-M-1-Producing Klebsiella pneumoniae and Mechanisms Leading to In Vivo Carbapenem Resistance Development. Journal of Clinical Microbiology, 2006, 44, 2831-2837. | 3.9 | 126 |
| 284 | Stepwise Upregulation of the Pseudomonas aeruginosa Chromosomal Cephalosporinase Conferring High-Level Î²-Lactam Resistance Involves Three AmpD Homologues. Antimicrobial Agents and Chemotherapy, 2006, 50, 1780-1787. | 3.2 | 164 |
| 285 | Hypermutation in natural bacterial populations: consequences for medical microbiology. Reviews in Medical Microbiology, 2005, 16, 25-32. | 0.9 | 6 |
| 286 | Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clinical Microbiology and Infection, 2005, 11, 690-703. | 6.0 | 134 |
| 287 | Contribution of clonal dissemination and selection of mutants during therapy to Pseudomonas aeruginosa antimicrobial resistance in an intensive care unit setting. Clinical Microbiology and Infection, 2005, 11, 887-892. | 6.0 | 38 |
| 288 | Hypermutation Is a Key Factor in Development of Multiple-Antimicrobial Resistance in Pseudomonas aeruginosa Strains Causing Chronic Lung Infections. Antimicrobial Agents and Chemotherapy, 2005, 49, 3382-3386. | 3.2 | 274 |

| # | Article | IF | Citations |
|---|---|---|---|
| 289 | Molecular Mechanisms of Î²-Lactam Resistance Mediated by AmpC Hyperproduction in Pseudomonas aeruginosa Clinical Strains. Antimicrobial Agents and Chemotherapy, 2005, 49, 4733-4738. | 3.2 | 146 |
| 290 | CTX-M-10 Linked to a Phage-Related Element Is Widely Disseminated among Enterobacteriaceae in a Spanish Hospital. Antimicrobial Agents and Chemotherapy, 2005, 49, 1567-1571. | 3.2 | 70 |
| 291 | Detection and Susceptibility Testing of Hypermutable Pseudomonas aeruginosa Strains with the Etest and Disk Diffusion. Antimicrobial Agents and Chemotherapy, 2004, 48, 2665-2672. | 3.2 | 64 |
| 292 | Lack of Association between Hypermutation and Antibiotic Resistance Development in Pseudomonas aeruginosa Isolates from Intensive Care Unit Patients. Antimicrobial Agents and Chemotherapy, 2004, 48, 3573-3575. | 3.2 | 60 |
| 293 | Hypermutation and the Preexistence of Antibiotic-Resistant Pseudomonas aeruginosa Mutants: Implications for Susceptibility Testing and Treatment of Chronic Infections. Antimicrobial Agents and Chemotherapy, 2004, 48, 4226-4233. | 3.2 | 138 |
| 294 | Epidemiological relatedness of methicillin-resistant Staphylococcus aureus from a tertiary hospital and a geriatric institution in Spain. Clinical Microbiology and Infection, 2004, 10, 339-342. | 6.0 | 16 |
| 295 | Evaluation of the NCCLS Extended-Spectrum Î²-Lactamase Confirmation Methods for<i>Escherichia coli</i>with Isolates Collected during Project ICARE. Journal of Clinical Microbiology, 2003, 41, 3142-3146. | 3.9 | 59 |
| 296 | Genes Encoding TEM-4, SHV-2, and CTX-M-10 Extended-Spectrum Î²-Lactamases Are Carried by Multiple<i>Klebsiella pneumoniae</i>Clones in a Single Hospital (Madrid, 1989 to 2000). Antimicrobial Agents and Chemotherapy, 2002, 46, 500-510. | 3.2 | 178 |
| 297 | Epidemiology of Extended-Spectrum Â-Lactamase-Producing Enterobacter Isolates in a Spanish Hospital during a 12-Year Period. Journal of Clinical Microbiology, 2002, 40, 1237-1243. | 3.9 | 119 |
| 298 | TEM-71, a Novel Plasmid-Encoded, Extended-Spectrum Î²-Lactamase Produced by a Clinical Isolate of Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2002, 46, 2000-2003. | 3.2 | 12 |
| 299 | Mutation and Evolution of Antibiotic Resistance: Antibiotics as Promoters of Antibiotic Resistance?. Current Drug Targets, 2002, 3, 345-349. | 2.1 | 57 |
| 300 | Mechanisms of Decreased Susceptibility to Cefpodoxime in Escherichia coli. Antimicrobial Agents and Chemotherapy, 2002, 46, 3829-3836. | 3.2 | 79 |
| 301 | The mismatch repair system (mutS, mutL and uvrD genes) in Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants. Molecular Microbiology, 2002, 43, 1641-1650. | 2.5 | 243 |
| 302 | Characterization of the GO system ofPseudomonas aeruginosa. FEMS Microbiology Letters, 2002, 217, 31-35. | 1.8 | 47 |
| 303 | Characterization of the GO system of Pseudomonas aeruginosa. FEMS Microbiology Letters, 2002, 217, 31-35. | 1.8 | 1 |
| 304 | Performance of the VITEK2 system for identification and susceptibility testing of routine Enterobacteriaceae clinical isolates. International Journal of Antimicrobial Agents, 2001, 17, 371-376. | 2.5 | 18 |
| 305 | Validation of the VITEK2 and the advance expert system with a collection of enterobacteriaceae harboring extended spectrum or inhibitor resistant Î²-lactamases. Diagnostic Microbiology and Infectious Disease, 2001, 41, 65-70. | 1.8 | 17 |
| 306 | Characterization of Clinical Isolates of<i>Klebsiella pneumoniae</i>from 19 Laboratories Using the National Committee for Clinical Laboratory Standards Extended-Spectrum Î²-Lactamase Detection Methods. Journal of Clinical Microbiology, 2001, 39, 2864-2872. | 3.9 | 170 |

| # | Article | IF | Citations |
|---|---|---|---|
| 307 | Prevalence of extended-spectrum Î²-lactamases in group-1 Î²-lactamase-producing isolates. Clinical Microbiology and Infection, 2001, 7, 278-282. | 6.0 | 6 |
| 308 | Nucleotide Sequence and Characterization of a Novel Cefotaxime-Hydrolyzing Î²-Lactamase (CTX-M-10) Isolated in Spain. Antimicrobial Agents and Chemotherapy, 2001, 45, 616-620. | 3.2 | 106 |
| 309 | Nontuberculous Mycobacteria in Patients with Cystic Fibrosis. Clinical Infectious Diseases, 2001, 32, 1298-1303. | 5.8 | 83 |
| 310 | Molecular Characterization of FOX-4, a New AmpC-Type Plasmid-Mediated Î²-Lactamase from an Escherichia coli Strain Isolated in Spain. Antimicrobial Agents and Chemotherapy, 2000, 44, 2549-2553. | 3.2 | 50 |
| 311 | Outbreak of a Multiresistant Klebsiella pneumoniae Strain in an Intensive Care Unit: Antibiotic Use as Risk Factor for Colonization and Infection. Clinical Infectious Diseases, 2000, 30, 55-60. | 5.8 | 160 |
| 312 | OXA-24, a Novel Class D Î²-Lactamase with Carbapenemase Activity in an <i>Acinetobacter baumannii</i> Clinical Strain. Antimicrobial Agents and Chemotherapy, 2000, 44, 1556-1561. | 3.2 | 226 |
| 313 | Pneumococcal psoas abscess: report of two cases. Clinical Microbiology and Infection, 2000, 6, 168-169. | 6.0 | 9 |
| 314 | High Frequency of Hypermutable <i>Pseudomonas aeruginosa</i> in Cystic Fibrosis Lung Infection. Science, 2000, 288, 1251-1253. | 12.6 | 1,322 |
| 315 | Evaluation of the Wider System, a New Computer-Assisted Image-Processing Device for Bacterial Identification and Susceptibility Testing. Journal of Clinical Microbiology, 2000, 38, 1339-1346. | 3.9 | 48 |
| 316 | Ampicillin-Sulbactam and Amoxicillin-Clavulanate Susceptibility Testing of <i>Escherichia coli</i> Isolates with Different Î²-Lactam Resistance Phenotypes. Antimicrobial Agents and Chemotherapy, 1999, 43, 862-867. | 3.2 | 27 |
| 317 | MICROSATELLITE MARKERS IN THE INDIRECT ANALYSIS OF THE STEROID 21-HYDROXYLASE GENE. Prenatal Diagnosis, 1997, 17, 429-434. | 2.3 | 16 |
| 318 | Analysis of steroid 21-hydroxylase gene mutations in the Spanish population. Human Genetics, 1995, 96, 198-204. | 3.8 | 112 |
| 319 | Evolution of<i>Pseudomonas aeruginosa</i>Pathogenicity: From Acute to Chronic Infections. , 0, , 433-444. | | 10 |
| 320 | Duration of Treatment for Pseudomonas aeruginosa Bacteremia: a Retrospective Study. Infectious Diseases and Therapy, 0, , . | 4.0 | 6 |
| 321 | Comparison of Ceftolozane/Tazobactam Infusion Regimens in a Hollow-Fiber Infection Model against Extensively Drug-Resistant Pseudomonas aeruginosa Isolates. Microbiology Spectrum, 0, , . | 3.0 | 1 |
| 322 | CARB-ES-19 Multicenter Study of Carbapenemase-Producing Klebsiella pneumoniae and Escherichia coli From All Spanish Provinces Reveals Interregional Spread of High-Risk Clones Such as ST307/OXA-48 and ST512/KPC-3. Frontiers in Microbiology, 0, 13, . | 3.5 | 20 |